Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: Neuropharmacology. 2022 Dec 23;225:109387. doi: 10.1016/j.neuropharm.2022.109387

Fig. 1.

Fig. 1.

Atorvastatin treatment reduced cholesterol content in N2A cells. Cells were treated with atorvastatin (0.1 –10 μM) or vehicle for 24 hr in DMEM supplemented with 10% lipoprotein-deficient serum. Total and unesterified cholesterol content were determined in cell lysates in the presence and absence of cholesterol esterase, respectively, using an Amplex Red cholesterol assay. (A) Cholesterol in N2A cells is unesterified (membrane) cholesterol. There was no difference in the membrane and total cholesterol content. (B) Atorvastatin (Ator) treatment reduced cholesterol content in a concentration-dependent manner. (C) Representative western blot images of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR, ∼95 kDa) following Ator treatment. (D) Ator treatment led to an increase in HMGCR experssion in a concentration-dependent manner. Data are presented with scatter plots as well as mean ± SEM. **p<0.01, ****p<0.0001 vs. vehicle